Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via info@isa-pharma.com. Read more…
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 fold Modi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant […]
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more
Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage […]
Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to […]
